|
rs25487
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Haplotype analysis of XRCC1 Arg194Trp (C/T) and Arg399Gln (G/A) revealed that the frequency of the T-A haplotype was significantly higher in PC patients.
|
17196815 |
2007 |
|
rs25487
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Based on these results, the XRCC1-Arg399Gln polymorphism might be a risk factor for PCa and it could be considered as a prognostic and predictive biomarker for susceptible men.
|
30160806 |
2018 |
|
rs25487
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In summary, we suggest that XRCC1 Arg399Gln might be significantly associated with development of Pca.
|
25262700 |
2015 |
|
rs25487
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Among the three polymorphisms, we found that the XRCC1 Arg399Gln variant allele was associated with increased PCa risk (adjusted odd ratio [OR]: 1.67, 95% confident interval [CI]: 1.11-2.51), but the XRCC1 Arg194Trp variant allele had a 38% reduction in risk of PCa (adjusted OR: 0.62, 95% CI: 0.41-0.93).
|
17486273 |
2007 |
|
rs25487
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the results of this meta-analysis show that the XRCC1-Arg399Gln polymorphism may be associated with an increased risk for prostate cancer under the homozygote model and the recessive model.
|
25927275 |
2015 |
|
rs1799782
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Overall, there was no obvious association between XRCC1 Arg194Trp polymorphism and prostate cancer</span> risk (Trp vs. Arg: OR = 1.02, 95%CI 0.84-1.25, P = 0.824; TrpTrp vs. ArgArg: OR = 1.17, 95%CI 0.83-1.66, P = 0.374; TrpTrp/ArgTrp vs. ArgArg: OR = 1.00, 95%CI 0.79-1.28, P = 0.990; TrpTrp vs. ArgArg/ArgTrp: OR = 1.20, 95%CI 0.85-1.68, P = 0.301).
|
24492938 |
2014 |
|
rs1799782
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Among the three polymorphisms, we found that the XRCC1 Arg399Gln variant allele was associated with increased PCa risk (adjusted odd ratio [OR]: 1.67, 95% confident interval [CI]: 1.11-2.51), but the XRCC1 Arg194Trp variant allele had a 38% reduction in risk of PCa (adjusted OR: 0.62, 95% CI: 0.41-0.93).
|
17486273 |
2007 |
|
rs1799782
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Haplotype analysis of XRCC1 Arg194Trp (C/T) and Arg399Gln (G/A) revealed that the frequency of the T-A haplotype was significantly higher in PC patients.
|
17196815 |
2007 |
|
rs1799782
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In this meta-analysis, we found that both Arg399Gln and Arg194Trp polymorphisms were not related to overall PCa risk.
|
21647176 |
2011 |
|
rs25489
|
|
|
0.030 |
GeneticVariation |
BEFREE |
However, there was no significant risk of PCa associated with Arg280His polymorphism.
|
17486273 |
2007 |
|
rs25489
|
|
|
0.030 |
GeneticVariation |
BEFREE |
And XRCC1-Arg280His polymorphism is likely to be related with prostate cancer risk under the heterozygote model and the dominant model.
|
25927275 |
2015 |
|
rs25489
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We conclude that the XRCC1 Arg280His polymorphism may be protective against the development of high-grade late toxicity after radiotherapy in prostate cancer patients.
|
21345510 |
2011 |
|
rs1041258260
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the present study was to analyze the effect of XPG Asp 1104His and XRCC1 Arg309Gln polymorphisms on risk of prostate cancer in north Indian population.
|
21670956 |
2012 |
|
rs25490
|
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings suggest that the c.910A>G polymorphism of the XRCC1 gene is associated with susceptibility to Pca in Chinese men, the G-allele conferring higher risk.
|
23244143 |
2012 |
|
rs777272152
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The aim of the present study was to analyze the effect of XPG Asp 1104His and XRCC1 Arg309Gln polymorphisms on risk of prostate cancer in north Indian population.
|
21670956 |
2012 |
|
rs1870134
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Among these eight SNPs investigated, only XPC rs1870134 CG/CC variant genotypes were associated with a decreased risk of prostate cancer under a dominant genetic model (adjusted odds ratio [OR] = 0.77, 95% confidence interval [CI] = 0.64-1.91, P = 0.003).
|
27974699 |
2017 |
|
rs2228001
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The combined analysis of XPC Lys939Gln and XPC-PAT variants showed that patients who inherited (Lys/Gln + PAT D/D) genotypes were protected against prostate cancer development compared to controls.
|
30552616 |
2019 |
|
rs2228001
|
|
|
0.050 |
GeneticVariation |
BEFREE |
These analyses suggest that XPC gene PAT+/-polymorphism, but not rs2228001, likely contributes to susceptibility to PCa.
|
24093803 |
2013 |
|
rs2228001
|
|
|
0.050 |
GeneticVariation |
BEFREE |
This is the first report on the studies of XPC and XRCC1 Arg194Trp polymorphisms in PC, and our present data suggest that XPC Lys939Gln and the T-A haplotype of XRCC1 Arg194Trp and Arg399Gln may be risk factors for PC in Japanese.
|
17196815 |
2007 |
|
rs2228001
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The purpose of this study was to evaluate the relationship between single-nucleotide polymorphism (SNP) rs2228001 in xeroderma pigmentosum group C (XPC), SNP rs4073 in interleukin 8 (IL8), and SNP rs2279744 in mouse double minute 2 (MDM2) homolog gene with PCa susceptibility.
|
26135929 |
2015 |
|
rs2228001
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Analyses of the XPC Lys939Gln polymorphism did not show an association with PCa risk.
|
22682619 |
2012 |
|
rs2807031
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
|
29892016 |
2018 |
|
rs2807031
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
|
25217961 |
2014 |
|
rs114780236
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
12 new susceptibility loci for prostate cancer identified by genome-wide association study in Japanese population.
|
31562322 |
2019 |
|
rs619824
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, our study suggests that rs619824 and rs2486758 polymorphisms are associated with PCa risk.
|
21656827 |
2011 |